Why the study?
Does cyclic Ang-(1-7) improve cardiac remodeling and endothelial function in rats with myocardial infarction?
Does cyclic Ang-(1-7) improve cardiac remodeling and endothelial function in rats with myocardial infarction?
A stabilized analogue of Ang-(1-7) attenuated adverse cardiac remodeling and improved hemodynamics and endothelial function in a rat model of myocardial infarction.
No immediate clinical implications for MI; leaves open translation of cAng-(1-7) analogues to human remodeling.
Modulation of renin-angiotensin system (RAS) by angiotensin-(1-7) (Ang-(1-7)) is an attractive approach to combat the detrimental consequences of myocardial infarction (MI). However Ang-(1-7) has limited clinical potential due to its unfavorable pharmacokinetic profile. We investigated effects of a stabilized, thioether-bridged analogue of Ang-(1-7) called cyclic Ang-(1-7) in rat model of myocardial infarction. Rats underwent coronary ligation or sham surgery. Two weeks thereafter infusion with 0.24 or 2.4 μg/kg/h cAng-(1-7) or saline was started for 8 weeks. Thereafter, cardiac morphometric and hemodynamic variables as wells as aortic endothelial function were measured. The average infarct size was 13.8% and was not changed by cAng-(1-7) treatment. MI increased heart weight and myocyte size, which was restored by cAng-(1-7) to sham levels. In addition, cAng-(1-7) lowered left ventricular end-diastolic pressure and improved endothelial function. The results suggest that cAng-(1-7) is a promising new agent in treatment of myocardial infarction and warrant further research.
No takes yet. Share an insight, caveat, or question.
Durik et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: